DDInter825 DDInter1158
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from
An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease . Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent . Throughout the late seventies and the eighties, important research initiatives developed stable mesalazine formulations like the eudragit-S coating of Asacol brand mesalazine and the Pentasa brand's encapsulation of mesalazine within microgranules . In the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce the risk of colorectal cancer in conditions like ulcerative colitis is maintained.[A174019,A174022]
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olsalazine
Olsalazine {u} (Compound) resembles {v} (Compound) Mesalazine
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dopamine
Dopamine {u} (Compound) resembles {v} (Compound) Mesalazine
Glimepiride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methyldopa
Methyldopa {u} (Compound) resembles {v} (Compound) Mesalazine
Glimepiride {u} (Compound) causes {v} (Side Effect) Vasodilation procedure
Vasodilation procedure {u} (Side Effect) is caused by {v} (Compound) Mesalazine
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olsalazine
Olsalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diflunisal
Diflunisal {u} (Compound) resembles {v} (Compound) Mesalazine
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dopamine
Dopamine {u} (Compound) resembles {v} (Compound) Carbidopa
Carbidopa {u} (Compound) resembles {v} (Compound) Mesalazine
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diflunisal
Diflunisal {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olsalazine
Olsalazine {u} (Compound) resembles {v} (Compound) Mesalazine
Glimepiride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methyldopa
Methyldopa {u} (Compound) resembles {v} (Compound) Carbidopa
Carbidopa {u} (Compound) resembles {v} (Compound) Mesalazine
Glimepiride {u} (Compound) causes {v} (Side Effect) Weight increased
Weight increased {u} (Side Effect) is caused by {v} (Compound) Carbidopa
Carbidopa {u} (Compound) resembles {v} (Compound) Mesalazine
Glimepiride {u} (Compound) causes {v} (Side Effect) Sweating
Sweating {u} (Side Effect) is caused by {v} (Compound) Diflunisal
Diflunisal {u} (Compound) resembles {v} (Compound) Mesalazine
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine (Compound) resembles Mesalazine (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Dopamine and Dopamine (Compound) resembles Mesalazine (Compound)
Glimepiride may cause a minor interaction that can limit clinical effects when taken with Methyldopa and Methyldopa (Compound) resembles Mesalazine (Compound)
Glimepiride (Compound) causes Vasodilation procedure (Side Effect) and Vasodilation procedure (Side Effect) is caused by Mesalazine (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal (Compound) resembles Mesalazine (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Dopamine and Dopamine (Compound) resembles Carbidopa (Compound) and Carbidopa (Compound) resembles Mesalazine (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine (Compound) resembles Mesalazine (Compound)
Glimepiride may cause a minor interaction that can limit clinical effects when taken with Methyldopa and Methyldopa (Compound) resembles Carbidopa (Compound) and Carbidopa (Compound) resembles Mesalazine (Compound)
Glimepiride (Compound) causes Weight increased (Side Effect) and Weight increased (Side Effect) is caused by Carbidopa (Compound) and Carbidopa (Compound) resembles Mesalazine (Compound)
Glimepiride (Compound) causes Sweating (Side Effect) and Sweating (Side Effect) is caused by Diflunisal (Compound) and Diflunisal (Compound) resembles Mesalazine (Compound)